ClinicalTrials.Veeva

Menu
The trial is taking place at:
H

Holdsworth House Medical Practice | Sydney, Australia

Veeva-enabled site

Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis

B

Bioventus

Status and phase

Active, not recruiting
Phase 2

Conditions

Osteoarthritis, Knee

Treatments

Biological: PTP-001
Other: Placebo control

Study type

Interventional

Funder types

Industry

Identifiers

NCT05100225
KOA-21-02

Details and patient eligibility

About

Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in individuals with knee osteoarthritis (OA).

Full description

This is a multiple arm, multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-arm, phase 2 study of intra-articular administration of an allogeneic human placental tissue particulate (PTP-001) for the treatment of knee osteoarthritis. The study is planned to be conducted outside the United States. A total of approximately 210 participants are planned to be randomized to receive 1 of 2 doses of PTP-001 (100 mg or 200 mg) or saline vehicle control (placebo) injection. The purpose of the trial is to evaluate the efficacy, safety and tolerability of a single low dose and high dose of PTP-001 compared to placebo over a 26-week period.

Enrollment

210 estimated patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:

    1. Male or female, aged 40 to 80 years

    2. Symptomatic knee OA with Kellgren-Lawrence radiographic classification of 2 or 3 (mild or moderate) as assessed by the central reading facility

    3. Target knee pain ≥ 20 and ≤ 40 out of 50 the WOMAC®NRS 3.1 pain questionnaire (sum of 5 questions) at screening and baseline

    4. Onset of symptomatic OA of the target knee was at least 6 months prior to screening

    5. Insufficient or failed response or intolerance to analgesics and/or non-steroidal anti-inflammatory drugs, as reported by the participant

    6. IF FEMALE, must meet all of the following:

      • Not breast feeding
      • Not planning to become pregnant during the study
      • If of childbearing potential, must have a negative pregnancy test result within 72 hours prior to receiving the intra-articular injection, and must commit to the use of a highly effective form of birth control (See Appendix A) for at least 12 weeks after the injection
    7. Willingness to remain on the same oral "rescue" (as needed) analgesic as the only pharmacologic treatment for knee pain during the study

    8. Willingness to abstain from taking any illicit or unauthorized medications for treatment of OA or any other concurrent condition during the study

    9. Written informed consent is obtained from the participant

Exclusion criteria

  • Participants are excluded from the study if any of the following criteria apply:

    1. Participant is non-ambulatory (unable to walk >50 feet without assistance)

    2. Clinically severe obesity as defined by the National Institutes of Health (body mass target ≥40 kg/m2)

    3. Contralateral knee pain equal to or exceeding the pain in the target knee (on the WOMAC® NRS3.1 pain questionnaire) at screening and/or baseline

    4. Clinically significant effusion of the target knee at either the screening or baseline visits determined by physical examination (e.g., ballotable patella or positive bulge sign). Note: Participants presenting with effusion may be enrolled in the study after undergoing knee aspiration to remove excess fluid in the target joint.

    5. Severe (excessive) malalignment of the tibial-femoral axis, assessed radiographically

    6. Presence of active infection of the target knee or systemic infection requiring treatment within the 3 months prior to screening

    7. Clinical diagnosis of inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, etc.) established by clinical history, examination, or serology

    8. Participant is receiving, has received, or plans to receive any of the following therapies

      • Prior administration of hyaluronic acid, extended release corticosteroid (e.g., Zilretta®), platelet-rich plasma (PRP), or stem cell therapies by intra-articular injection(s) of the target knee within 6 months prior to screening
      • Prior intra-articular corticosteroid within 3 months prior to screening or into any other joint within 30 days prior to screening
      • Current chronic systemic use of corticosteroids in doses exceeding 10 mg prednisolone-equivalents daily
      • Treatment with any investigational therapy (drug, device, or biologic) within 3 months prior to screening or is planned for the duration of the study
      • Treatment with immunosuppressive medication or chemotherapy within the past 5 years
    9. Chronic use of narcotics or alcohol abuse within the past 6 months prior to screening

    10. Surgery to the target knee (including arthroscopy) within 6 months prior to receiving the intra-articular injection or planned surgery to the target knee within 6 months after the injection

    11. Participant previously underwent arthroplasty of the target knee

    12. Presence of joint instability or complaints of locking, intermittent limitation in range of motion, or loose body sensation, suggestive of internal derangement of the knee (either extremity)

    13. Symptomatic OA of the non-target knee that is not responsive to paracetamol (acetaminophen) or oral nonsteroidal anti-inflammatory drugs (NSAIDs).

    14. Diagnosis of lower extremity gout or pseudo-gout in the past 6 months

    15. Osteonecrosis of either knee

    16. Significant acute (within the past 3 months) injury to the target knee

    17. History of receiving a solid organ or hematologic transplant

    18. History of malignancy, radiotherapy, or chemotherapy for malignancy within the past 5 years, except for basal or squamous cell carcinoma of the skin

    19. History of prior radiation therapy of the target knee

    20. History of autoimmune disease affecting the musculoskeletal system

    21. Known (documented) history of acquired immune deficiency syndrome or human immunodeficiency virus

    22. Any condition causing pain in or around the target knee (e.g., radiating pain, pain in another region of the ipsilateral lower extremity) that may interfere with assessment(s) of the target knee

    23. Other chronic pain anywhere in the body that requires the chronic use of analgesic medications, such as fibromyalgia, neuropathic pain, low back pain, etc.

    24. Presence of contraindications for use of 3 g/day of orally administered paracetamol/acetaminophen due to known hypersensitivity or hepatic impairment.

    25. Known presence of any concurrent medical condition (e.g., hematologic renal, hepatic, cardiac, or coagulation abnormalities) that in the investigator's judgment would interfere with the required study assessments and study participation

    26. Participant is involved in litigation (e.g., worker's compensation) for a medical condition or injury at any anatomical site

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

210 participants in 3 patient groups, including a placebo group

PTP-001 200 mg
Experimental group
Description:
A single intra-articular injection in the target knee of PTP-001 200 mg.
Treatment:
Biological: PTP-001
PTP-001 100 mg
Experimental group
Description:
A single intra-articular injection in the target knee of PTP-001 100 mg.
Treatment:
Biological: PTP-001
Placebo/saline
Placebo Comparator group
Description:
A single intra-articular injection in the target knee of 4mL of placebo control - physiological saline (0.9% sodium chloride injection, USP).
Treatment:
Other: Placebo control

Trial contacts and locations

14

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems